Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo - PubMed (original) (raw)
. 2012 Feb 21;109(8):3035-40.
doi: 10.1073/pnas.1111573109. Epub 2012 Feb 6.
Mohamed Abdel-Mohsen, John Guatelli, Mark Skasko, Alexander Monto, Katsuya Fujimoto, Steven Yukl, Warner C Greene, Helen Kovari, Andri Rauch, Jacques Fellay, Manuel Battegay, Bernard Hirschel, Andrea Witteck, Enos Bernasconi, Bruno Ledergerber, Huldrych F Günthard, Joseph K Wong; Swiss HIV Cohort Study
Affiliations
- PMID: 22315404
- PMCID: PMC3286922
- DOI: 10.1073/pnas.1111573109
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo
Satish K Pillai et al. Proc Natl Acad Sci U S A. 2012.
Abstract
The antiviral potency of the cytokine IFN-α has been long appreciated but remains poorly understood. A number of studies have suggested that induction of the apolipoprotein B mRNA editing enzyme, catalytic polypeptide 3 (APOBEC3) and bone marrow stromal cell antigen 2 (BST-2/tetherin/CD317) retroviral restriction factors underlies the IFN-α-mediated suppression of HIV-1 replication in vitro. We sought to characterize the as-yet-undefined relationship between IFN-α treatment, retroviral restriction factors, and HIV-1 in vivo. APOBEC3G, APOBEC3F, and BST-2 expression levels were measured in HIV/hepatitis C virus (HCV)-coinfected, antiretroviral therapy-naïve individuals before, during, and after pegylated IFN-α/ribavirin (IFN-α/riba) combination therapy. IFN-α/riba therapy decreased HIV-1 viral load by -0.921 (±0.858) log(10) copies/mL in HIV/HCV-coinfected patients. APOBEC3G/3F and BST-2 mRNA expression was significantly elevated during IFN-α/riba treatment in patient-derived CD4+ T cells (P < 0.04 and P < 0.008, paired Wilcoxon), and extent of BST-2 induction was correlated with reduction in HIV-1 viral load during treatment (P < 0.05, Pearson's r). APOBEC3 induction during treatment was correlated with degree of viral hypermutation (P < 0.03, Spearman's ρ), and evolution of the HIV-1 accessory protein viral protein U (Vpu) during IFN-α/riba treatment was suggestive of increased BST-2-mediated selection pressure. These data suggest that host restriction factors play a critical role in the antiretroviral capacity of IFN-α in vivo, and warrant investigation into therapeutic strategies that specifically enhance the expression of these intrinsic immune factors in HIV-1-infected individuals.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Fig. 1.
IFN-α/riba treatment strongly suppresses HIV-1 viremia. (A) Blood plasma HIV-1 viral load before, during, and after treatment. (B) CD4+ cell counts before, during, and after treatment. (C) Log10 reduction in HIV-1 viral load plotted against percent change in CD4+ lymphocyte count. Reported P values were obtained using a paired Wilcoxon test (A and B) or a Spearman's ρ (C).
Fig. 2.
APOBEC3G, APOBEC3F, and BST-2/tetherin are significantly induced in CD4+ T cells during IFN-α/riba treatment. (A) APOBEC3, tetherin/BST2, and IFN-stimulated gene 15 (ISG15) expressions in unfractionated PBMCs (mean expression is plotted, and error bars represent SEM). (B) APOBEC3, tetherin/BST2, and ISG15 expression in isolated CD4+ T cells. The expression of ISG15 was measured as a positive control in these experiments to confirm IFN-α exposure and response during the treatment period. *P < 0.05; **P < 0.005. (C) Relationship between restriction factor induction and ISG15 induction in CD4+ T cells during IFN-α/riba treatment. (D) Relationship between HIV-1 viral load reduction and restriction factor induction in CD4+ T cells during IFN-α/riba treatment.
Fig. 3.
APOBEC3-induced HIV-1 hypermutation during IFN-α/riba treatment. (A) Relationship between GG to AG (APOBEC3G dinucleotide context) viral hypermutation level during treatment and APOBEC3G relative mRNA copy number. (B) Relationship between GA to AA (APOBEC3F dinucleotide context) viral hypermutation level during treatment and APOBEC3F relative mRNA copy number. (C) Relative frequency of APOBEC3G- and APOBEC3F-associated mutations (mean values are plotted and error bars represent SEM). (D) Example of treatment-associated viral hypermutation from a single individual. Red tick mark, GG → AG mutation (APOBEC3G pattern); cyan, GA → AA (APOBEC3F pattern); green, GC → AC; magenta, GT → AT; black, all other mutations; yellow, deletion (compared with pretreatment consensus sequence). Shaded sequences in the bottom half of the panel represent pretreatment PBMC-derived HIV-1 DNA clones, and the sequences in the top, unshaded one of the panel represent PBMC-derived HIV-1 DNA clones from the IFN-α/riba treatment period. Sequences span an ∼500-bp region of the env and nef genes, and ∼20 clones per time point per individual were analyzed.
Fig. 4.
Evolution of the HIV-1 Vpu protein during IFN-α/riba treatment. (A) Amino acid sequences of HIV-1 Vpu generated from nine individuals before and during IFN-α/riba treatment. Dashes indicate identity to the HXB2 reference sequence. Vpu positions 11 and 61 are shaded. (B) Effects of A11G and S61A treatment-associated Vpu mutations on Vpu-mediated down-regulation of BST-2 surface expression measured by flow cytometry. Shaded histograms represent mock DNA-transfected cells (negative control).
Similar articles
- IFN-α induces APOBEC3G, F, and A in immature dendritic cells and limits HIV-1 spread to CD4+ T cells.
Mohanram V, Sköld AE, Bächle SM, Pathak SK, Spetz AL. Mohanram V, et al. J Immunol. 2013 Apr 1;190(7):3346-53. doi: 10.4049/jimmunol.1201184. Epub 2013 Feb 20. J Immunol. 2013. PMID: 23427247 - Genetic and phenotypic analyses of sequential vpu alleles from HIV-infected IFN-treated patients.
Vanwalscappel B, Rato S, Perez-Olmeda M, Díez Fuertes F, Casartelli N, Alcami J, Mammano F. Vanwalscappel B, et al. Virology. 2017 Jan;500:247-258. doi: 10.1016/j.virol.2016.10.028. Epub 2016 Nov 15. Virology. 2017. PMID: 27855354 - TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+ T cells across the virological synapse.
Blanchet FP, Stalder R, Czubala M, Lehmann M, Rio L, Mangeat B, Piguet V. Blanchet FP, et al. Retrovirology. 2013 Jan 11;10:6. doi: 10.1186/1742-4690-10-6. Retrovirology. 2013. PMID: 23311681 Free PMC article. - Sites of action of HIV-1 Vpu in BST-2/tetherin downregulation.
Arias JF, Iwabu Y, Tokunaga K. Arias JF, et al. Curr HIV Res. 2012 Jun;10(4):283-91. doi: 10.2174/157016212800792423. Curr HIV Res. 2012. PMID: 22524176 Review. - Emerging role of the host restriction factor tetherin in viral immune sensing.
Hotter D, Sauter D, Kirchhoff F. Hotter D, et al. J Mol Biol. 2013 Dec 13;425(24):4956-64. doi: 10.1016/j.jmb.2013.09.029. Epub 2013 Sep 26. J Mol Biol. 2013. PMID: 24075872 Review.
Cited by
- Innate protection against intrarectal SIV acquisition by a live SHIV vaccine.
Sui Y, Meyer TJ, Fennessey CM, Keele BF, Dadkhah K, Ma C, LaBranche CC, Breed MW, Kramer JA, Li J, Howe SE, Ferrari G, Williams LD, Cam M, Kelly MC, Shen X, Tomaras GD, Montefiori D, Greten TF, Miller CJ, Berzofsky JA. Sui Y, et al. JCI Insight. 2024 May 21;9(12):e175800. doi: 10.1172/jci.insight.175800. JCI Insight. 2024. PMID: 38912579 Free PMC article. - Membrane Protein OTOF Is a Type I Interferon-Induced Entry Inhibitor of HIV-1 in Macrophages.
Ding H, Zhang X, Zhu Z, Wang S, Xiong Y, Shang H, Liang G. Ding H, et al. mBio. 2022 Aug 30;13(4):e0173822. doi: 10.1128/mbio.01738-22. Epub 2022 Jul 18. mBio. 2022. PMID: 35862790 Free PMC article. - HIV-reservoir size is not affected either by HCV coinfection or by direct acting antivirals (DAAs) therapy.
Álvarez B, Navarrete-Muñoz MA, Briz V, Olmedillas-López S, Nistal S, Cabello A, Prieto L, Górgolas M, García-Arranz M, Benito JM, Rallón N. Álvarez B, et al. Sci Rep. 2022 Mar 24;12(1):5095. doi: 10.1038/s41598-022-08871-0. Sci Rep. 2022. PMID: 35332180 Free PMC article. - Mutagenic Activity of AID/APOBEC Deaminases in Antiviral Defense and Carcinogenesis.
Shilova ON, Tsyba DL, Shilov ES. Shilova ON, et al. Mol Biol. 2022;56(1):46-58. doi: 10.1134/S002689332201006X. Epub 2022 Feb 12. Mol Biol. 2022. PMID: 35194245 Free PMC article. - Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients.
Grubczak K, Grzeszczuk A, Groth M, Hryniewicz A, Kretowska-Grunwald A, Flisiak R, Moniuszko M. Grubczak K, et al. Viruses. 2021 Jul 25;13(8):1448. doi: 10.3390/v13081448. Viruses. 2021. PMID: 34452314 Free PMC article.
References
- Piot P, Bartos M, Ghys PD, Walker N, Schwartländer B. The global impact of HIV/AIDS. Nature. 2001;410:968–973. - PubMed
- Simon JH, Gaddis NC, Fouchier RA, Malim MH. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med. 1998;4:1397–1400. - PubMed
- Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 2002;418:646–650. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- IK2 CX000520/CX/CSRD VA/United States
- 1K01DA024654/DA/NIDA NIH HHS/United States
- AI081668/AI/NIAID NIH HHS/United States
- R21MH083573/MH/NIMH NIH HHS/United States
- R37 AI081668/AI/NIAID NIH HHS/United States
- R21 MH083573/MH/NIMH NIH HHS/United States
- R56 AI091573/AI/NIAID NIH HHS/United States
- R01 NS051132/NS/NINDS NIH HHS/United States
- R01 AI081668/AI/NIAID NIH HHS/United States
- K01 DA024654/DA/NIDA NIH HHS/United States
- R01NS051132/NS/NINDS NIH HHS/United States
- P30 AI027763/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials